piperacillin--tazobactam-drug-combination and Birth-Weight

Antibiotics are often used in neonates despite the absence of relevant dosing information in drug labels. For neonatal dosing, clinicians must extrapolate data from studies for adults and older children, who have strikingly different physiologies. As a result, dosing extrapolation can lead to increased toxicity or efficacy failures in neonates. Driven by these differences and recent legislation mandating the study of drugs in children and neonates, an increasing number of pharmacokinetic studies of antibiotics are being performed in neonates. These studies have led to new dosing recommendations with particular consideration for neonate body size and maturation. Herein, we highlight the available pharmacokinetic data for commonly used systemic antibiotics in neonates.

Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Birth Weight; Body Size; Cephalosporins; Child; Clindamycin; Glycopeptides; Humans; Infant; Infant, Newborn; Medication Reconciliation; Meropenem; Metronidazole; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins